Disc Medicine, Inc. (IRON) stock
IRONNasdaqPharmaceutical PreparationsFiscal year ends December 31
$76.57−0.02 (-0.03%)
Close on Nov 17, 2026Market cap $2.94BP/E –Yield –
Disc Medicine ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Disc Medicine's ebitda for the twelve months ending Jun 30, 2026 was -$268.91M. For fiscal 2025 it was -$235.74M. The highest annual figure on record is -$30.90M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$235.74M | – |
| FY2024 | Dec 31, 2024 | -$129.56M | – |
| FY2023 | Dec 31, 2023 | -$91.03M | – |
| FY2022 | Dec 31, 2022 | -$47.39M | – |
| FY2021 | Dec 31, 2021 | -$30.90M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$64.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$69.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$66.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -$67.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$61.33M | – |
| Q1 FY2025 | Mar 31, 2025 | -$39.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$34.54M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.44M | – |
| Q4 FY2023 | Dec 31, 2023 | -$29.69M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.10M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.46M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.94M | – |
See a number that looks wrong?